CN107903252A - Triazole derivative and its application in the medicine for preparing treatment liver diseases - Google Patents
Triazole derivative and its application in the medicine for preparing treatment liver diseases Download PDFInfo
- Publication number
- CN107903252A CN107903252A CN201711047043.5A CN201711047043A CN107903252A CN 107903252 A CN107903252 A CN 107903252A CN 201711047043 A CN201711047043 A CN 201711047043A CN 107903252 A CN107903252 A CN 107903252A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- acid
- liver
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 63
- 208000019423 liver disease Diseases 0.000 title claims abstract description 25
- 150000003852 triazoles Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 98
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- -1 triazole compound Chemical class 0.000 claims abstract description 23
- 239000012453 solvate Substances 0.000 claims abstract description 13
- 239000002207 metabolite Substances 0.000 claims abstract description 11
- 201000007270 liver cancer Diseases 0.000 claims description 14
- 208000014018 liver neoplasm Diseases 0.000 claims description 14
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 14
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 13
- 208000004930 Fatty Liver Diseases 0.000 claims description 13
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 13
- 208000010706 fatty liver disease Diseases 0.000 claims description 13
- 210000004185 liver Anatomy 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 208000034189 Sclerosis Diseases 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 230000002440 hepatic effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 125000001475 halogen functional group Chemical group 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 238000007614 solvation Methods 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000002253 acid Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 11
- 230000037213 diet Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 11
- 208000019425 cirrhosis of liver Diseases 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000003513 alkali Substances 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 6
- 102100025136 Macrosialin Human genes 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 229960000516 bezafibrate Drugs 0.000 description 5
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 5
- 229960002297 fenofibrate Drugs 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 230000002969 morbid Effects 0.000 description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 4
- 229960000836 amitriptyline Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000256856 Vespidae Species 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 2
- FCUIRBQXJWMGLZ-YLUJEXTNSA-N 2-(3-decanoyl-7-hydroxy-1-benzofuran-4-yl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C=12C(C(=O)CCCCCCCCC)=COC2=C(O)C=CC=1C=1OC2=CC(O)=CC(O)=C2C(=O)C=1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O FCUIRBQXJWMGLZ-YLUJEXTNSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010004659 Biliary cirrhosis Diseases 0.000 description 2
- 0 CC(C)CC[C@](C1IC1)C(/C1=C/C*/C(/NC(c2cccc(OCC(C(C3C(OC(F)(F)F)=CC=CC3)=N)=C(*)C3CC3)c2)=O)=C\C=C1)=NN Chemical compound CC(C)CC[C@](C1IC1)C(/C1=C/C*/C(/NC(c2cccc(OCC(C(C3C(OC(F)(F)F)=CC=CC3)=N)=C(*)C3CC3)c2)=O)=C\C=C1)=NN 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 190000032366 Miboplatin Chemical compound 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- MOFINMJRLYEONQ-UHFFFAOYSA-N [N].C=1C=CNC=1 Chemical class [N].C=1C=CNC=1 MOFINMJRLYEONQ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- SLYTULCOCGSBBJ-FCQHKQNSSA-I disodium;2-[[(2s)-2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+) Chemical compound [Na+].[Na+].[Gd+3].CCOC1=CC=C(C[C@@H](CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)N(CC([O-])=O)CC([O-])=O)C=C1 SLYTULCOCGSBBJ-FCQHKQNSSA-I 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- PBVFROWIWWGIFK-KWCOIAHCSA-N fluoromethylcholine (18F) Chemical compound [18F]C[N+](C)(C)CCO PBVFROWIWWGIFK-KWCOIAHCSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229950002777 miboplatin Drugs 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 238000004262 preparative liquid chromatography Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 229960005137 succinic acid Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- YPZMPEPLWKRVLD-PJEQPVAWSA-N D-Glycero-D-gulo-Heptose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O YPZMPEPLWKRVLD-PJEQPVAWSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000013231 NASH rodent model Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- YAVVGPBYBUYPSR-UHFFFAOYSA-N benzene;oxygen Chemical compound [O].C1=CC=CC=C1 YAVVGPBYBUYPSR-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229960002059 gadoversetamide Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 1
- 229960001601 obeticholic acid Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- DRKHJSDSSUXYTE-UHFFFAOYSA-L oxidanium;2-[bis[2-[carboxylatomethyl-[2-(2-methoxyethylamino)-2-oxoethyl]amino]ethyl]amino]acetate;gadolinium(3+) Chemical compound [OH3+].[Gd+3].COCCNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NCCOC DRKHJSDSSUXYTE-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229940054870 urso Drugs 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- 229950009233 zinostatin stimalamer Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of triazole compound for being used to treat liver diseases.The compound is compound, its pharmaceutically acceptable salt, hydrate, solvate or metabolite shown in formula I.The compound can be used in being prepared into treatment and/or prevent the medicine of liver diseases.
Description
Technical field
The invention belongs to biomedicine technical field, is related to triazole derivative and its is preparing treatment liver diseases
Application in medicine.
Background technology
Liver diseases are the common disease and frequently-occurring disease in China, including fatty liver, various acute, chronic hepatitis, liver fibrosis, liver
The series of disease such as hardening, liver cancer, these hepatopathys are mostly by obesity, medicine, excessive consumption of alcohol, B-mode and Hepatitis C Virus sense
Dye etc. causes.Estimate according to the World Health Organization, every year due to death toll caused by various types of hepatitis be about 1,400,000 to
1500000, the 7th is occupied in various diseases.And the World Health Organization alerts, hepatitis, which will exceed AIDS quickly, becomes the mankind the
6 big Health Killers.China has become the country for paying most social cost for hepatitis, hepatic sclerosis and liver cancer in the world.According to me
The statistics of disease prevention and control center of state：China increases virus hepatitis newly per annual report and falls ill patient up to more than 1,000,000, its
Middle hepatitis B patient accounting maintains 80% or so；National hepatitis B virus surface antigen carrier surpasses 1.2 hundred million people, accounts for country's total population
8%~10%, account for nearly the 1/3 of global HBV carrier number；And as many as nearly 1,000,000 people of annual hepatitis B new infections person.
According to rice Intranet, China hepatopathy medication market total scale is risen to 2015 by 233.28 hundred million yuan in 2010
Year 537.005 hundred million yuan, 2014 and 2015 China's hepatosis treating medicine market in general scales be respectively 459.61 hundred million yuan with
537.05 hundred million yuan, growth rate 16.85%；It is expected that hepatosis treating medicine market total scale will keep the annual growth of 15-20%.
Wherein, fatty liver (Fatty liver) this indication is directed to, it is domestic at present also without medicine official listing.State
The seal oil omega-3 polyunsaturated fatty acids of interior Zhejiang Jin Nuokang biologies, application listing are in registration phase.In addition, shellfish courage difficult to understand
Sour (obeticholic acid) obtains U.S. FDA approval on May 27th, 2016, and first granted indication is primary to treat
Property biliary cirrhosis, its be used for the indication of non-alcoholic fatty liver at present US and European be in 3 phases clinic, in day
This is in 2 phase clinical investigation phases.Liver fibrosis (Liver fibrosis) is directed to, has carried out the medicine of this indication at present
Totally 46：Wherein listed 2, registration 1,3 phases are 2 clinical, 2 phases are 8 clinical, 1 phase is 4 clinical, preclinical 28, stop grinding 1
It is a.The two marketed drugs are respectively biological agent gamma- interferon, the Traditional Chinese Medicine Fuzheng of Shanghai Huanghai Sea pharmacy of star medicine again
Huayu Capsule.Hepatic sclerosis (cirrhosis) is directed to, through further screening, it is primary to have marketing data and segment indication
Property biliary cirrhosis (Primary Biliary Cirrhosis, PBC) medicine totally 2, be respectively urso, Austria
Shellfish cholic acid.In addition, it is related to treatment or the diagnostic medicine totally 14 that " hepatocellular carcinoma or liver tumour " at home and abroad lists：More soft ratio
The U.S. appropriate former times monoclonal antibody of star, iodine [131I], cis-platinum, Miboplatin, 18F- fluorocholine chloride, DW-166HC, Immuncell-LC, restructuring
Human Inter Leukin-2, arsenious acid, Gadoxetic acid disodium, Zinostatin stimalamer, Gadoversetamide, pirarubicin and Sorafenib.
Wherein this 14 medicines except Miboplatin, 18F- fluorocholine chloride, DW-166HC, Immuncell-LC and Zinostatin this
This 5 kinds of ester is introduced into Chinese market, remaining 9 kinds in Discussion on Chinese Listed.Having 2 kinds in 9 kinds of medicines, (Gadoxetic acid disodium, gadolinium are not filled in
Amine) it is used for medical imaging diagnosis use, there was only the targeted therapy that Sorafenib is used for liver cancer at present, it is reported that taking Suo Lafei
The adverse reaction that the liver cancer patient of Buddhist nun occurs is more.
In order to reach the therapeutic effect for being preferably directed to liver diseases such as fatty liver, hepatic sclerosis, liver fibrosis, liver cancer etc.,
To better meet the clinical demand with market, thus it is safer, efficient for treating liver diseases there is an urgent need to develop going out
Medicine.
The content of the invention
The technical problems to be solved by the invention are that do not have suitable medicine, Yi Jike to solve existing indication
The defects of taking existing clinical medicine, and a kind of new triazole compound is provided, which can be used for liver diseases
Such as the treatment and/or prevention of fatty liver, hepatic sclerosis, liver fibrosis, liver cancer etc..
The present invention provides a kind of compound shown in formula I, its pharmaceutically acceptable salt, hydrate, solvate,
Metabolite,
Wherein, the R1For selected from phenyl, pyridine radicals, cyclohexyl or cyclopenta, each of which is optionally by 1-3 R4Take
Generation；Or R1For optionally by 1-2 R4Or the cyclopropyl of phenyl substitution；It is preferred that R1For selected from by 1-3 R4Substituted phenyl；
The R2For selected from C1-4Alkyl, halo C1-4Alkyl, unsubstituted C3-8Cycloalkyl or optionally substituted C3-8
Cycloalkyl；It is preferred that R2For selected from cyclopropyl, cyclobutyl or cyclopenta；
The R3For selected from H, C1-10Alkyl, C3-8Cycloalkyl, C2-10Alkenyl, C2-10Alkynyl, aryl, heteroaryl or heterocycle
Base, all substituents are alternatively by 1,2 or 3 selected from halogen, oxo, C1-6Alkyl, C3-8Cycloalkyl, heterocyclic radical, phenyl, benzene oxygen
Base, halogen ,-CN ,-O-R5、-C(O)-R5、-OC(O)-R5-C(O)-O-R5、-N(R5)-C(O)-O-R6、-N(R5)-C(O)-R6、-
N(R5)-C(O)-N(R5)(R6) and-C (O)-N (R5)(R6) substituent substitution, wherein alkyl, cycloalkyl, heterocyclic radical, phenyl,
With phenoxy group alternatively C is selected from by 1,2 or 31-6Alkyl, C3-8Cycloalkyl, C1-6The substituent of alkoxy, hydroxyl and halogen takes
Generation；
The R4For selected from halogen, C1-6Alkyl, halo C1-6Alkyl, C1-6Alkoxy, halo C1-6Alkoxy ,-SR7Or ring
Propyl group；
The R5And R6Independently selected from by hydrogen, C1-6Alkyl or C3-8Cycloalkyl forms；Or R5And R6When with they institute
Heterocycle is formed when the nitrogen of connection links together；
According to some embodiments of the present invention, preferably R3For selected from H, C1-10Alkyl or C3-8Cycloalkyl；
According to some embodiments of the present invention, more preferably R3For selected from H, methyl, ethyl, isopropyl, the tert-butyl group or ring third
Base；
The R7For selected from C1-6Alkyl, preferably R7For selected from methyl, ethyl, isopropyl or the tert-butyl group；
X is selected from O or NH, and preferably X is selected from O.
Thus, throughout this manual, those skilled in the art can be to R described in compound shown in Formulas I1~R7And X
Group and its substituent make choice, with provide it is described in the embodiment of the present invention, stablize Formulas I shown in compound or its
Pharmaceutically acceptable salt, hydrate, solvate or metabolite.
According to an embodiment of the invention, compound shown in Formulas I of the present invention, for following any compound：
Compound of formula I of the present invention can be prepared according to the chemical synthesis process of this area routine, its step and bar
Part refers to this area similar the step of reacting and condition.Reaction dissolvent used in each reactions steps of the present invention does not have
Especially limitation, any solvent that can be dissolved starting material to a certain extent and not suppress reaction are included in the present invention.
In addition, many similar changes of this area, equivalent substitution, or it is equal to solvent described in the invention, solvent combination, and solvent
The different proportion of combination, is accordingly to be regarded as the scope of the present invention.
The present invention gives a kind of method of compound described in formula I, its synthetic route are as follows：
Carboxylic acid shown in Formulas I-a reacts with the amine shown in Formulas I-b under conditions of acid amides is suitably formed.For example, to
The mixing of compound of the atent solvent as shown in the Formulas I-a in n,N-Dimethylformamide (DMF) and the compound shown in Formulas I-b
In thing, addition (2- (7- azepine -1H- benzotriazole -1- bases) -1,1,3,3- tetramethylurea hexafluorophosphates (HATU) and alkali,
Typically N-methylmorpholine, and at about room temperatures by mixture keep about 3-18 is small when.When the completion of the reaction, after progress
Processing obtains the product of compound shown in Formulas I.
The compounds of this invention also can be separated and purified according to standard technique well known to those skilled in the art.Such as pure
A kind of particularly useful technology is preparative liquid chromatography when changing compound, it is flowed out using mass spectrum as detection from chromatographic column
Pure compound means.
Preparative LC-MS be for purify small organic molecule, compound as described herein standard effective ways.Can be with
Change liquid chromatogram (LC) and the method for mass spectrum (MS), so that crude product preferably separates and improve detections of the MS to sample.Prepare
The optimization of type gradient LC methods, which is related to, changes pillar, volatility eluant, eluent and conditioning agent and gradient.These methods are in optimization preparative
LC-MS methods are well-known in field, are adopted and are used to purifying compound.This kind of method is described in the following references：
RosentreterU, Huber U.；Optimal fraction collecting in preparative LC/MS；J Comb
Chem.；2004；6 (2), 159-64 and Leister W, Strauss K, Wisnoski D, Zhao Z, Lindsley C.,
Development of a custom high-throughput preparative liquidchromatography/mass
spectrometer platform for the preparativepurification and analytical analysis
of compound libraries；J Comb Chem.；2003；5(3)；322-9.
Compound shown in Formulas I of the present invention, it can add the work such as formulation carrier or excipient as active ingredient
The additive of addition is allowed so that preparation is made for pharmaceuticals additive.Tablet, granule, capsule, interior may be appropriately used
Take the oral administration preparation for the form that liquid preparation etc. is suitable for from alimentary canal absorption, the warp such as injection, suppository and patch, paste
The non-oral administration agent such as skin absorbent, and solid pharmaceutical preparation, liquid preparation, needs from the such as circulation, keeping quality Shi Yong Time
Solid solvent is dissolved etc. to any form of form of generally use in the past in appropriate solvent.In addition, in order to improve this chemical combination
The bioavilability and stability of thing, can also use the administration system for including the preparation techniques such as microcapsules, micropowder, inclusion
System.
The present invention provides a kind of pharmaceutical composition, it includes the compound of formula I, its pharmaceutically acceptable salt, water
Compound, solvate or metabolite, and pharmaceutic adjuvant；The compound of formula I, its pharmaceutically acceptable salt, hydration
The dosage of thing, solvate or metabolite can be therapeutically effective amount.
Although reactive compound may be administered alone in compound of formula I of the present invention, it is preferred that as pharmaceutical composition
The form of (such as preparation) provides, and the composition includes at least one reactive compound of the invention and one or more can medicine
With carrier, auxiliary agent, excipient, diluent, filler, buffer, stabilizer, preservative, lubricant or people in the art
Other materials known to member and optional other treatment or prevention agent.Thus, present invention also offers medicine as defined above
Compositions and the method for preparing pharmaceutical composition, this method are included at least one reactive compound and one as defined above
Kind or a variety of pharmaceutical acceptable carrier, excipient, buffer, auxiliary agent, stabilizer or other materials as described herein mix.
In the pharmaceutical composition, the compound of formula I, its pharmaceutically acceptable salt, hydrate, solvation
The dosage of thing or metabolite, can be therapeutically effective amount.
The pharmaceutic adjuvant can be those auxiliary materials widely used in medicine production field.Auxiliary material is mainly used for offer one
A safe and stable and functional pharmaceutical composition, can also provide method, and active ingredient is with institute after making subject's receiving administration
Expected rate dissolution, or promote subject to receive active ingredient after composition is administered and effectively absorbed.
Present invention also offers the compound of formula I, its pharmaceutically acceptable salt, hydrate, solvate or metabolism
Product, the application in the medicine for preparing treatment and/or prevention liver diseases.The liver diseases include but not limited to fat
Liver, hepatic sclerosis, liver fibrosis, liver cancer etc..
Unless otherwise prescribed, all technical terms and scientific terminology used herein have claimed theme fields
Standard implication.If to Mr. Yu's term there are multiple definition, then to be defined herein as standard.When Referral URL or other identifier or
Address, it should be appreciated that such identifier can change, and the customizing messages on internet can change, but mutual by searching for
Networking can find equal information.Reference this type of information can be obtained and open propagated.
It should be understood that above-mentioned general explanation and following detailed description are merely illustrative of, to the present invention and from
This limitation.The singulative being used in the present invention, such as " one kind " or "one", including plural, unless otherwise prescribed.This
Outside, term " comprising " is open limits and non-enclosed.
Unless otherwise indicated, the present invention using mass spectrum, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA technology or
The conventional method of pharmacology detection, each step and condition can refer to the operating procedure and condition of this area routine.Unless otherwise specified,
The present invention is using the standard name of analytical chemistry, Synthetic Organic Chemistry and medical chemistry and standard laboratory step and technology.
In some cases, standard technique is used for chemical synthesis, chemical analysis, medicine preparation, formula and medicine delivery and patient
Treatment.
Used term " pharmaceutically acceptable " in the present invention, is for those compounds, material, composition
And/or for formulation, within the scope of reliable medical judgment, being contacted suitable for the tissue with human and animal makes for they
With without excessive toxicity, irritation, allergic reaction or other problems or complication, with rational interests/Hazard ratio phase
Claim.
Term " pharmaceutically acceptable salt " refers to the salt of the compounds of this invention, by present invention discover that there is specific substitution
It is prepared by the compound of base and the acid of relative nontoxic or alkali., can when in the compound of the present invention containing relatively acid functional group
To pass through the side for using the alkali of sufficient amount to be contacted with the neutral form of this kind of compound in pure solution or suitable atent solvent
Formula obtains base addition salts.Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino or magnesium salts or similar salt.
, can be by pure solution or suitable atent solvent when in the compound of the present invention containing relatively alkaline functional group
The mode contacted with the sour neutral form with this kind of compound of sufficient amount obtains acid-addition salts.Pharmaceutically acceptable acid addition
The example of salt includes inorganic acid salt, and the inorganic acid includes such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate radical, phosphoric acid, phosphorus
A sour hydrogen radical, dihydrogen phosphate, sulfuric acid, bisulfate ion, hydroiodic acid, phosphorous acid etc.；And acylate, the organic acid include
As acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, butanedioic acid, suberic acid, fumaric acid, lactic acid, mandelic acid,
Phthalic acid, benzene sulfonic acid, p-methyl benzenesulfonic acid, citric acid, the tartaric acid acid similar with methanesulfonic acid etc.；Further include amino acid (such as
Arginine etc.) salt, and such as glucuronic acid organic acid salt (referring to Berge et al., " Pharmaceutical
Salts”,Journal of Pharmaceutical Science 66:1-19(1977)).Some specificization of the present invention
Compound contains alkalescence and acid functional group, so as to be converted into any alkali or acid-addition salts.Preferably, in a usual manner
Salt is contacted with alkali or acid, then separate parent compound, thus the neutral form of raw compounds again.The parent fo of compound with
The difference of the form of its various salt is some physical properties, such as the different solubility in polar solvent.
" pharmaceutically acceptable salt " used in the present invention belongs to the derivative of the compounds of this invention, wherein, by with acid
The parent compound is modified into salt or with the mode of alkali into salt.The example of pharmaceutically acceptable salt includes but not limited to：Alkali
Inorganic acid or the alkali metal of acylate, acid group such as carboxylic acid or organic salt of base such as amine etc..Pharmaceutically acceptable salt
Include the quaternary ammonium salt of conventional avirulent salt or parent compound, such as the salt that nontoxic inorganic acid or organic acid are formed.
Conventional avirulent salt includes but not limited to those salt derived from inorganic acid and organic acid, the inorganic acid or organic acid
Selected from Aspirin, 2- ethylenehydrinsulfonic acids, acetic acid, ascorbic acid, benzene sulfonic acid, benzoic acid, bicarbonate radical, carbonic acid,
Citric acid, edetic acid(EDTA), ethane disulfonic acid, ethane sulfonic acid, fumaric acid, glucoheptose, gluconic acid, glutamic acid, glycolic, hydrobromic acid,
Hydrochloric acid, hydriodate, hydroxyl naphthalene, isethionic acid, lactic acid, lactose, dodecyl sodium sulfonate, maleic acid, malic acid, mandelic acid, methane
Sulfonic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, propionic acid, salicylic acid, stearic acid, sub- acetic acid, butanedioic acid, ammonia
Base sulfonic acid, p-aminobenzene sulfonic acid, sulfuric acid, tannin, tartaric acid and p-methyl benzenesulfonic acid.
" pharmaceutically acceptable salt " of the present invention can pass through conventional chemical by the parent compound containing acid group or base
Method synthesizes.Under normal circumstances, the preparation method of such salt is：In the mixture of water or organic solvent or both, via
The appropriate alkali or acid of these compounds and stoichiometry of free acid or alkali form are reacted to prepare.It is generally preferable that ether, second
The non-aqueous medias such as acetoacetic ester, ethanol, isopropanol or acetonitrile.
Some compounds of the present invention can exist with nonsolvated forms or solvation form, including hydrate forms.
In general, solvation form is suitable with non-solvated form, it is intended to be included within the scope.The present invention's is some
Compound can exist with polycrystalline or amorphous form.
The compound of the present invention can include the original of unnatural proportions on one or more atoms for forming the compound
Daughter isotope.For example, radioisotope labeled compound can be used, such as tritium (3H), iodine-125 (125I) or C-14 (14C).
The present invention compound all isotopics conversion, no matter radioactivity whether, be included within the scope of the present invention.
For medicine or pharmacologically active agents, term " effective dose " or " therapeutically effective amount " refer to nontoxic but can reach
To the medicine of Expected Results or enough dosages of medicament.For the peroral dosage form in the present invention, a kind of active material in composition
" effective dose " refer to when another active material is combined in said composition for the required dosage that achieves the desired results.Have
The definite of effect amount varies with each individual, and age and ordinary circumstance depending on acceptor, also depend on specific active material, closed in case
Suitable effective dose can be determined by those skilled in the art according to routine test.
Term " active ingredient ", " therapeutic agent ", " active material " or " activating agent " refers to a kind of chemical entities, it can have
The therapeutic purpose disorder of effect ground, disease or illness.
Term "comprising" is open language, that is, includes the content specified by the present invention, but be not precluded from otherwise
Content.
According to an embodiment of the invention, triazole compound preparation of the present invention is convenient, production cost is relatively low.
According to an embodiment of the invention, triazole compound of the present invention, it can significantly inhibit NASH morbid state
The balloon sample enlargement of liver cell, and reduce CD68 Positive area rates.Have for nonalcoholic fatty liver disease (NASH)
There is the effect of good, and effect is better than existing medicine.
According to an embodiment of the invention, triazole compound of the present invention, it is to rat hepatocytes degeneration necrosis
Degree mitigates, and can obviously reduce rat annulus hyperplasia degree, has obvious effect of anti hepatic fibrosis, and dosage is small, peace
Quan Xinggao.
According to an embodiment of the invention, triazole compound of the present invention, has resisting liver cancer activity, to human liver cancer
The growth of Cell Line HepG2, Hep3b and SMMC-7721 has good inhibiting effect.
According to an embodiment of the invention, triazole compound of the present invention, it is right in heart hERG experiments
HERG passages do not have obvious inhibitory action, show good cardiac safety.
So compound of the present invention can be as the medicine of liver diseases, for treating and/or preventing liver disease
Disease, such as treating and/or preventing the liver diseases such as fatty liver, hepatic sclerosis, liver fibrosis, liver cancer.Of the present invention three
Nitrogen azole compounds, available for the medicine for being prepared into treatment and/or prevention liver diseases.
Embodiment
The solution of the present invention is explained below in conjunction with embodiment.It will be understood to those of skill in the art that following
Embodiment is merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.Particular technique or bar are not specified in embodiment
Part, carried out according to the described technology of document in the art or condition or according to product description.Agents useful for same or instrument
Production firm person is not specified in device, and being can be with conventional products that are commercially available.
The embodiment provides compound shown in Formulas I or its pharmaceutically acceptable salt, hydrate, solvation
Thing or metabolite, compound shown in formula Ι or its pharmaceutically acceptable salt, hydrate, solvate or metabolism production
The purposes of the compound of the method and intermediate of thing, pharmaceutical composition, and the present invention in medicine preparation.
The preparation of 1 compound I-1 of embodiment
By compound I-a1 (440mg, 1.05mmol), compound I-b1 (203mg, 1.0mmol), (2- (7- azepines -1H-
Benzotriazole -1- bases) -1,1,3,3- tetramethylurea hexafluorophosphate (HATU) (456mg, 1.2mmol) and N-methylmorpholine (13
μ L, 1.2mmol) add in DMF, when 70 DEG C of stirrings 8 of insulation are small.It is concentrated under reduced pressure and removes solvent, residue is suspended in acetonitrile,
And solid product is separated by filtering, is washed with water (80mL), acetonitrile (80mL), acetone (80mL) and done under vacuo
It is dry, it is product Compound I-1 so as to obtain the off-white powder (yield 62%) of 374mg.(LC/MS：[M+H]+605)。
The preparation of 2~embodiment of embodiment, 5 compound I-2~I-5
The preparation method of compound I-2~I-5, is tested in the way of similar to embodiment 1, but what is used rises
Beginning raw material compound is different.Reaction is finished, and separation product respectively obtains compound I-2~I-5, and product is tested through LC/MS
Card.
Compound I-2 (LC/MS：[M+H]+523)。
Compound I-3 (LC/MS：[M+H]+568)。
Compound I-4 (LC/MS：[M+H]+565)。
Compound I-5 (LC/MS：[M+H]+549)。
Effect of 6 compound of the present invention of embodiment in ldl receptor gene rejects mouse NASH models
The present invention has inquired into higher fatty acid/high courage of the fatty liver and incidence of hepatitis in the known characteristic morbid state with NASH
Sterol diet (Western diet) load ldl receptor gene rejecting mouse (Yoshimatsu M. etc.,
Int.J.Exp.Path., 85,335-43 (2004)) in effect.
Use animal：Male LDL receptor gene knockout mice is used in experiment.During 13 weeks since about 8 week old,
It is freely absorbed higher fatty acid/High cholesterol diet, make to suffer from NASH.Higher fatty acid/High cholesterol diet load is carried out to mouse,
Implement blood sampling and body weight determination after 1 week.
According to making between group not have discrepant mode to be divided into following groups in lipid and weight in blood plasma：Control group (0.5% first
Base cellulose aqueous solution), compound 0.25mg/kg gives group (medicine group of the present invention) and fenofibrate shown in formula I-1
Special 100mg/kg gives group.
Medicine is given：Administration capacity is 5ml/kg weight, and 1 day 1 time oral administration, 0.5% methyl is given to control group
Cellulose aqueous solution, gives group to medicine group of the present invention, fenofibrate and gives compound and Fei Nuo shown in formula I-1 respectively
The liquid of Bei Te.Administration phase is 12 weeks.
Observe and check method：After administration, liver is extracted under yellow Jackets (50mg/kg) anesthesia, using more
After polyformaldehyde is fixed, Hematoxylin-eosin stained preparation and the immunostaining sample to CD68 are made.Contaminated using Hematoxylin-eosin
Colour code sheet, under the conditions of blind examination, by the balloon sample enlargement of liver cell according to following standard (Kleiner etc., Hepatology 41,
1313-21,2005) score, it is shown in Table 1.Measured by image analysis system (WinROOF) in the liver under the conditions of blind examination
CD68 Positive area rates.
Table 1
| Grade | Scoring |
| Without balloon sample enlargement cell | 0 |
| Balloon sample enlargement cell is few | 1 |
| Balloon sample enlargement cell is more or notable | 2 |
The results show：(1) in the 0.25mg/kg administrations of medicine group of the present invention, confirm to significantly inhibit the balloon sample of liver cell
Enlargement.In the 100mg/kg of fenofibrate gives group, confirm there is the tendency for suppressing balloon sample enlargement, but statistically not
Significantly.(2) in the 0.25mg/kg administrations of medicine group of the present invention, the CD68 Positive area rates in liver significantly reduce (drop
Low rate 85.5%).And the CD68 Positive area rates reduced rate of fenofibrate group is 75%.
The result shows that：Medicine group of the present invention is to suppressing the balloon sample enlargement effect of the liver cell of NASH morbid state and reducing
In CD68 Positive area rates, fenofibrate is superior to.
Compound shown in 7 Formulas I of the present invention of embodiment is lacking the KK-A of diet load using methionine/choliney
Effect in nonalcoholic fatty liver disease (NASH) model of mouse
This experiment discussion is known to lack diet (MCD diet) load by carrying out methionine/choline to experimental animal
The MCD diet loads of the pathogenesis of fatty liver for the characteristic morbid state for making there is NASH KK-Ay mouse (Nakano S. etc.,
Hepatol Res., 38 (10), 1026-39,2008) effect in.
Use animal：Male KK-Ay mouse are used in an experiment, start to allow mouse freely to absorb MCD drinks in about 12 week old
Food 16 weeks, makes to suffer from NASH.
Group is formed：In the way of weight does not have difference between group, it is divided into following groups：(MCD is drunk for normal diet group, control group
Food load), compound 0.25mg/kg shown in formula I-2 gives group (of the present invention group) and Bezafibrate 60mg/kg gives
Group.
Medicine is given：Given and carried out by mixed feeding.Control group is set freely to absorb the MCD diet of not drug containing, make the present invention
Group, which is freely absorbed, to be contained the MCD diet of compound shown in 0.00025% Formulas I -2, Bezafibrate is given group freely to absorb and is contained
The MCD diet of 0.06% Bezafibrate.Administration phase is 16 weeks.
Observation and inspection method：After giving, liver is extracted under yellow Jackets (50mg/kg) anesthesia, using more
After polyformaldehyde is fixed, Hematoxylin-eosin stained preparation is made.Under the conditions of blind examination, evaluation fatty liver scoring (Steatosis
score).The grade of fat deposition (Grade) is observed with enlargement ratio 100 again, according to its grade according to following standard by fat
Liver scores with 0 to 3, is shown in Table 2.
Table 2
| Grade | Scoring |
| Less than 5% | 0 |
| 5% with up to less than 33% | 1 |
| 33% with up to less than 66% | 2 |
| More than 66% | 3 |
As a result：In of the present invention group, the fatty liver scoring of whole examples is all 0, i.e. fat deposition almost disappears.In benzene
The 60mg/kg of Zha Beite is given in group, although fat deposition to be suppressed to the degree identical with normal diet group, is not arrived
The degree almost to disappear up to the fat deposition as of the present invention group.It follows that compared with Bezafibrate, institute of the present invention
State the fat deposition that compound shown in Formulas I more strongly suppresses one of NASH morbid state.The result shows that：Shown in Formulas I of the present invention
KK-A of the compound in the MCD diet loads of the animal pattern of NASHyIn mouse, show that the fat deposition of liver substantially reduces.Cause
This, compound of the invention is high as mammiferous non-alcohol fatty liver including humans, particularly severe degree
Nonalcoholic fatty liver disease prevention and/or therapeutic agent be useful.Compound shown in Formulas I of the present invention can be used for making
It is standby into treatment nonalcoholic fatty liver disease
(NASH) preventing/treating medicine, and its effect of drugs is better than existing medicine Bezafibrate.
Influence of the compound to Hepatic Fibrosis fibroplasia degree shown in 8 Formulas I of the present invention of embodiment
SPF grades of Wistar rats 46, weight 190g-220g, half male and half female.Rat be divided at random Normal group,
Model control group, positive control drug group, medicine group of the present invention, totally 4 groups.In addition to Normal group, other each groups rat skin first
The lower pure CCl of injection45ml/kg weight, is changed to that the CCl that concentration is 40% is subcutaneously injected later4Peanut oil solution 3ml/kg weight,
Every 3 days 1 time, totally 6 weeks.Feed normal solid feed, free water.
After modeling, the corresponding tested material of following dosage is given：By weight, positive drug group rat oral gavage colchicin
5mg·kg-1·d-1, compound 1mgkg shown in medicine group rat oral gavage Formulas I -4 of the present invention of the present invention-1·d-1, normally
Control group and model control group rat give the distilled water of same volume.Gavage 1 time daily, is used in conjunction 10 weeks, each group is after the last administration
When fasting 12 is small, weigh, through yellow Jackets intraperitoneal injection of anesthesia, take rat right leaflet liver, about 0.5 cm thick liver of clip
Tissue, neutral buffered formalin are fixed, and paraffin embedding, cuts into slices as 5 μ m thicks.Through multistage dehydration of alcohol, dimethylbenzene is transparent, makees HE
Dyeing, sirius red dye, and pathological tissue photo is shot under light microscopic, observe the situation of change of proliferation of fibrous tissue degree.Pass through
Found after observation pathological section：
Normal group：Lobuli hepatis structure complete display in liver tissues of rats, hepatic cell cords marshalling, no liver cell become
Necrosis, no cell infiltration, no fibroplasia；
Model control group：The visible liver cell of liver tissues of rats is disorganized, the denaturation of liver cell vacuole sample, necrosis, portal area
A large amount of proliferations of fibrous tissue are simultaneously dispersed in inflammatory cell infiltration, and the visible proliferation of fibrous tissue of most of rat extends to lobuli hepatis,
Separate lobuli hepatis and form pseudolobuli；
Positive drug group：Rat hepatocytes degeneration necrosis mitigates, the visible pseudolobuli of partial rat；
Medicine group of the present invention：Rat hepatocytes degeneration necrosis mitigates, the visible pseudolobuli of partial rat.
Light Microscopic observation, for proliferation of fibrous tissue situation with " ++++" for most serious, "-" is no fibroplasia.Normal control
Group liver tissues of rats section display is formed without liver fibrosis, and model group fibroplasia is obvious, illustrates model modeling success.Specifically
It the results are shown in Table 3.
3 each group rat tissue collagen fiber hyperplasia grading comparable situation of table
The result shows that：Medicine group of the present invention mitigates rat hepatocytes degeneration necrosis degree, can obviously reduce rat annulus
Hyperplasia degree.The medicine of compound shown in Formulas I of the present invention has obvious effect of anti hepatic fibrosis.It is and of the present invention
The ability of the anti-hepatic fibrosis of compound shown in Formulas I -4 is better than colchicin, and dosage is smaller than colchicin, security
It is high.
Experimental example 11：Using compound shown in mtt assay bounds evaluation I-5 to the growth inhibition effect of human hepatoma cell strain
1. method：Cell in growth logarithmic phase：HepG2 cell lines, Hep3b and SMMC-7721 with 1.5 ×
104Concentration kind is in 96 orifice plates.Original culture medium is sucked after cell culture 24h is adherent.Experiment is divided into blank control group, medicine
Treatment group.Blank group replaces 1640 culture mediums containing 10% hyclone；Drug-treated group, which is replaced, contains concentration for 100 μM, 50 μM,
The culture medium of 10 μM, 1 μM, 0.1 μM, 0.01 μM and 0.001 μM of Houttuynoid C.After cultivating 48h, concentration 5mg/ is added
The MTT of mL, continues to be put in CO2Incubator culture 4h, sucks 100 μ L of supernatant then along nutrient solution top, adds 100 μ L
10min is placed in DMSO, dark place, using microplate reader (Sunrise Products) measure light absorption value (wavelength 570nm), and according to suction
Light value calculates cell survival, and each processing sets 6 repeating holes.Cell survival rate (%)=Δ ODDrug-treated/ΔODBlank control×
100。
2. result：Compound shown in Formulas I -5 to HepG2 cell lines, Hep3b and
The growth of SMMC-7721 has significant inhibitory action.The compound suppresses HepG2 cell lines, Hep3b
With the IC of SMMC-7721 growths50Value is respectively：9nM、19nM、26nM.
Shown by above-described embodiment, compound is to HepG2 cell lines and SMMC-7721 shown in Formulas I of the invention
Growth there is good inhibiting effect.Thus prove, compound shown in Formulas I of the invention has resisting liver cancer activity, can be used for
Prepare medicines resistant to liver cancer.
20 heart hERG of embodiment is tested
Influence of the compound of the present invention to hERG potassium-channels is detected using manual patch clamp methods, as a result table
Compound described in bright 1-5 of the embodiment of the present invention, it is equal to the inhibitory action of hERG electric currents at highest test concentrations (30 μM)
Not up to IC50, i.e. IC50>30μM.So as to illustrate in the range of the detectable concentration of this experiment described in 1-5 of the embodiment of the present invention
Test sample compound there is no obvious inhibitory action to hERG passages.5 test samples show good in this trial stretch
Good cardiac safety.Amitriptyline (Amitriptyline) be the most widely used blocking hERG electric currents tool drug it
One, therefore positive reference substance, its IC are used as in this research50For 3.16 μM of (notes：In this research, positive reference substance
The IC50 that Amitriptyline suppresses hERG electric currents is 3.16 μM.This result is consistent with the result with document report
(Blockade of the HERG human cardiac K+channel by the antidepressant drug
amitriptyline.British Journal of Pharmacology.Jo,SH et al.,(2000).)).This shows this
Secondary experiment the result is that believable.
So compound of the present invention can be as the medicine of liver diseases, for treating and/or preventing liver disease
Disease, such as treating and/or preventing the liver diseases such as fatty liver, hepatic sclerosis, liver fibrosis, liver cancer.Of the present invention three
Nitrogen azole compounds, available for the medicine for being prepared into treatment and/or prevention liver diseases.
In the description of this specification, reference term " one embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means to combine the embodiment or example particular features, structures, materials, or characteristics described
It is contained at least one embodiment of the present invention or example.In the present specification, schematic expression of the above terms differs
Surely identical embodiment or example are referred to.Moreover, particular features, structures, materials, or characteristics described can be any
Combined in an appropriate manner in one or more embodiments or example.
Although the embodiment of the present invention has been shown and described above, it is to be understood that above-described embodiment is example
Property, it is impossible to limitation of the present invention is interpreted as, those of ordinary skill in the art are not departing from the principle of the present invention and objective
In the case of above-described embodiment can be changed within the scope of the invention, change, replace and modification.
Claims (7)
- A kind of 1. compound, its pharmaceutically acceptable salt, hydrate, solvate or metabolite shown in formula I；Wherein, the R1For selected from phenyl, pyridine radicals, cyclohexyl or cyclopenta, each of which is optionally by 1-3 R4Substitution；Or Person R1For optionally by 1-2 R4Or the cyclopropyl of phenyl substitution；The R2For selected from C1-4Alkyl, halo C1-4Alkyl, unsubstituted C3-8Cycloalkyl or optionally substituted C3-8Cycloalkanes Base；The R3For selected from H, C1-10Alkyl, C3-8Cycloalkyl, C2-10Alkenyl, C2-10Alkynyl, aryl, heteroaryl or heterocyclic radical, own Substituent is alternatively by 1,2 or 3 selected from halogen, oxo, C1-6Alkyl, C3-8Cycloalkyl, heterocyclic radical, phenyl, phenoxy group, halogen Element ,-CN ,-O-R5、-C(O)-R5、-OC(O)-R5-C(O)-O-R5、-N(R5)-C(O)-O-R6、-N(R5)-C(O)-R6、-N (R5)-C(O)-N(R5)(R6) and-C (O)-N (R5)(R6) substituent substitution, wherein alkyl, cycloalkyl, heterocyclic radical, phenyl, With phenoxy group alternatively C is selected from by 1,2 or 31-6Alkyl, C3-8Cycloalkyl, C1-6The substituent of alkoxy, hydroxyl and halogen takes Generation；The R4For selected from halogen, C1-6Alkyl, halo C1-6Alkyl, C1-6Alkoxy, halo C1-6Alkoxy ,-SR7Or ring third Base；The R5And R6Independently selected from by hydrogen, C1-6Alkyl or C3-8Cycloalkyl forms；Or R5And R6When connected to them Heterocycle is formed when nitrogen links together；The R7For selected from C1-6Alkyl；The X is selected from O or NH.
- 2. compound shown in Formulas I as claimed in claim 1, its pharmaceutically acceptable salt, hydrate, solvate or generation Thank to product, it is characterised in thatThe R1For selected from by 1-3 R4Substituted phenyl；The R2For selected from cyclopropyl, cyclobutyl or cyclopenta；The R3For selected from H, C1-10Alkyl or C3-8Cycloalkyl；The R7For selected from methyl, ethyl, isopropyl or the tert-butyl group；The X is selected from O.
- 3. compound shown in Formulas I as claimed in claim 2, its pharmaceutically acceptable salt, hydrate, solvate or generation Thank to product, it is characterised in thatThe R3For selected from H, methyl, ethyl, isopropyl, the tert-butyl group or cyclopropyl.
- 4. compound shown in Formulas I as claimed in claim 1, its pharmaceutically acceptable salt, hydrate, solvate or generation Thank to product, it is characterised in that compound shown in Formulas I of the present invention, for following any compound：
- 5. a kind of pharmaceutical composition, it includes such as compound of formula I according to any one of claims 1 to 4, it can pharmaceutically connect Salt, hydrate, solvate or the metabolite received, and pharmaceutic adjuvant；The compound of formula I, its is pharmaceutically acceptable Salt, hydrate, the dosage of solvate or metabolite can be therapeutically effective amount.
- 6. such as compound of formula I according to any one of claims 1 to 4, its pharmaceutically acceptable salt, hydrate, solvation Thing or metabolite, or pharmaceutical composition as claimed in claim 5 is in the medicine for preparing treatment and/or prevention liver diseases Application.
- 7. application as claimed in claim 6, it is characterised in that the liver diseases are fatty liver, hepatic sclerosis, liver fiber Change or liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711047043.5A CN107903252B (en) | 2017-10-31 | 2017-10-31 | Triazole derivative and application thereof in preparation of drugs for treating liver diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711047043.5A CN107903252B (en) | 2017-10-31 | 2017-10-31 | Triazole derivative and application thereof in preparation of drugs for treating liver diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107903252A true CN107903252A (en) | 2018-04-13 |
| CN107903252B CN107903252B (en) | 2020-04-24 |
Family
ID=61842140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711047043.5A Active CN107903252B (en) | 2017-10-31 | 2017-10-31 | Triazole derivative and application thereof in preparation of drugs for treating liver diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107903252B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015187499A1 (en) * | 2014-06-03 | 2015-12-10 | Gilead Sciences, Inc. | Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor |
-
2017
- 2017-10-31 CN CN201711047043.5A patent/CN107903252B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015187499A1 (en) * | 2014-06-03 | 2015-12-10 | Gilead Sciences, Inc. | Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor |
Non-Patent Citations (2)
| Title |
|---|
| R.B. 西尔弗曼 编: "《有机药物化学》", 31 January 2008 * |
| 孟令芝等编著: "《有机波谱分析》", 31 July 2016 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107903252B (en) | 2020-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107793400A (en) | Pyridine compounds and their and its application in the medicine for preparing treatment liver diseases | |
| TWI573794B (en) | Acid addition salt of trk inhibitor compound | |
| CN103432133B (en) | The purposes of nuclear receptor binding agents | |
| KR20160132029A (en) | Methods and compositions for modulating estrogen receptor mutants | |
| CN107922404A (en) | Chloroquine and clemizole compound are used for the purposes for treating inflammation and cancer | |
| KR20130142141A (en) | Pharmaceutical formulations of a substituted diaminopurine | |
| CN106167483A (en) | Can be used for compound, compositions and method that cholesterol is mobilized | |
| CN104024217B (en) | Three rings for treating or preventing the symptom related to endocrine dysfunction contain amino-compound | |
| US8299125B2 (en) | Water-soluble triterpenephenol compounds having antitumor activity and the preparation thereof | |
| CN105792830A (en) | Substituted gemcitabine bicyclic amide analogs and treatment methods using same | |
| CN107903252A (en) | Triazole derivative and its application in the medicine for preparing treatment liver diseases | |
| CN101863901B (en) | 2-(substituted phenyl)-2-(4,5,6,7-thiophane[3,2-c] pyridine-5(4H)-group)-N-substitute-acetamide as well as preparation method and application thereof | |
| CN110437285A (en) | Qinghaosu ruthenium metal complex and preparation method thereof and medical usage | |
| CN104292226B (en) | 9-hydroxy-risperidone amino acid derivatives and application thereof | |
| CN103467412B (en) | Drug chemical compound for gout | |
| CN103006631A (en) | Application of N-benzyl fatty acyl amide compound to preparation of neuroprotective drugs | |
| AU2020355939B2 (en) | Rutin compositions | |
| EP4204405A1 (en) | Polymorphs of an ssao inhibitor | |
| CN102675244B (en) | Thiazine amide derivatives and in the purposes preparing neurodegenerative disease medicine | |
| CN108250219B (en) | A kind of drug and preparation method thereof for treating thyroiditis | |
| CN109400647A (en) | One group of tenofovir diester compound and its salt, preparation method and its medicinal usage | |
| CN105175326B (en) | 5 methyl 2 (1H) Pyridione derivatives and its production and use | |
| AU2019209594B2 (en) | Metabolites of bictegravir | |
| CN106905348B (en) | A kind of drug and its preparation method and application preventing and treating acute kidney injury | |
| CN108218946A (en) | A kind of deoxycholic aicd class compound, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 430040 Room 509, Unit 1, Workshop No. 1, Accelerator Phase I Project of Wuhan Guanggu International Biomedical Enterprise, No. 388, Donghu New Technology Development Zone, Wuhan City, Hubei Province Applicant after: Wuhan Jiuzhou Yumin Medical Technology Co.,Ltd. Address before: 430000 East Lake New Technology Development Zone, Wuhan, Hubei 388, No. 388 hi tech two road, Wuhan Optics Valley international biomedical enterprise accelerator phase 1 workshop No. 1, unit 509. Applicant before: WUHAN ZHONGYU YUMIN MEDICINE TECHNOLOGY CO.,LTD. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Triazole derivatives and their application in the preparation of drugs for the treatment of liver diseases Effective date of registration: 20220323 Granted publication date: 20200424 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: Wuhan Jiuzhou Yumin Medical Technology Co.,Ltd. Registration number: Y2022420000073 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230322 Granted publication date: 20200424 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: Wuhan Jiuzhou Yumin Medical Technology Co.,Ltd. Registration number: Y2022420000073 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Triazole derivatives and their applications in the preparation of drugs for treating liver diseases Effective date of registration: 20230329 Granted publication date: 20200424 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: Wuhan Jiuzhou Yumin Medical Technology Co.,Ltd. Registration number: Y2023420000139 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20200424 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: Wuhan Jiuzhou Yumin Medical Technology Co.,Ltd. Registration number: Y2023420000139 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Triazole derivatives and their applications in the preparation of drugs for treating liver diseases Granted publication date: 20200424 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: Wuhan Jiuzhou Yumin Medical Technology Co.,Ltd. Registration number: Y2024980008025 |